Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Mirvaso Rhofade Prior Auth | Open…
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy N/A

    Mirvaso and Rhofade for Rosacea

    Customize your policy alerts

    Sign up for all UnitedHealthcare policy alerts

    Know when UnitedHealthcare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and reauthorization for Mirvaso (brimonidine 0.33% topical gel) and Rhofade (oxymetazoline 1% topical cream) for adult patients with rosacea. It applies to providers submitting requests under the UnitedHealthcare commercial pharmacy benefit.

    Policy Summary
    PayerUnitedHealthcare
    PolicyMirvaso and Rhofade for Rosacea
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of positive clinical response to therapy for reauthorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered medications
    12 monthsInitial authorization duration
    12 monthsReauthorization duration
    RosaceaInitial diagnosis requirement
    Positive response

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Reauthorization requirement

    Authorization Requirements

    Initial Authorization

    Covered when the following criterion is met:

    Initial authorization: The patient has a diagnosis of rosacea.

    Reauthorization

    Covered when the following criterion is met:

    Reauthorization: Documentation demonstrates a positive clinical response to therapy.

    Submission and Denial Risks

    Prior Authorization

    Initial Authorization Required

    Prior authorization is required for Mirvaso (brimonidine gel) or Rhofade (oxymetazoline cream). For initial authorization, the member must have a diagnosis of rosacea.

    • Initial authorization is issued for 12 months.
    Documentation Required

    Reauthorization Requirements

    For reauthorization, document a positive clinical response to Mirvaso or Rhofade therapy. When this criterion is met, authorization is issued for 12 months.

    • Reauthorization requires documentation of positive clinical response.
    • Authorization duration: 12 months.
    Documentation Required

    Response Documentation

    Submit documentation demonstrating the member’s positive clinical response to therapy with the reauthorization request. This response documentation is required for continued authorization.

    • Include clinical documentation supporting positive response to treatment.
    Denial Risk

    Missing Rosacea Diagnosis

    Initial authorization may be denied when a diagnosis of rosacea is not documented.

    • Document the rosacea diagnosis in the initial authorization request.
    Denial Risk

    No Documented Clinical Response

    Reauthorization may be denied when positive clinical response to therapy is not documented.

    • Provide clinical response documentation with the reauthorization request.

    Medication and Indication Overview

    Mirvaso (brimonidine) 0.33% topical gel and Rhofade (oxymetazoline) 1% topical cream are alpha-adrenergic agonists indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults.

    Covered Condition

    Covered Condition
    Covered conditionPersistent (nontransient) facial erythema of rosacea
    Patient populationAdults
    Treatment contextTopical treatment

    Initial Therapy

    Initial Therapy

    Initial authorization will be approved when the following criterion is met:

    Initial therapy: The patient has a diagnosis of rosacea.

    Authorization will be issued for 12 months.

    Continuation Therapy

    Continuation Therapy

    Reauthorization will be approved when the following criterion is met:

    Continuation therapy: Documentation of positive clinical response to therapy.

    Authorization will be issued for 12 months.

    Policy Summary
    PayerUnitedHealthcare
    PolicyMirvaso and Rhofade for Rosacea
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of positive clinical response to therapy for reauthorization.
    SourceLink
    On This Page
    Authorization RequirementsSubmission and Denial RisksMedication and Indication OverviewCovered ConditionInitial TherapyContinuation Therapy